

Supplemental Table 1

Characteristics of patients with both MSI and dMMR IHC testing receiving ICI therapy in any line.

Acronyms: MSI-H, microsatellite instability high; MSS, microsatellite stable; ICI, immune checkpoint inhibitor; NOS, not otherwise specified; ECOG, Eastern Cooperative Oncology Group; dMMR, deficient mismatch repair; IHC, immunohistochemistry; TMB, tumor mutational burden; NGS, next generation sequencing; PDL1, programmed death-ligand 1; TPS, tumor proportion score; BMI, body mass index

	MSI-H (N=38)	MSS (N=32)	Total (N=70)	p value
Age at Therapy Start				0.6
Median (Q1, Q3)	69.0 (61.0, 74.0)	70.5 (62.0, 75.0)	70.0 (62.0, 74.8)	
Practice Type				0.378
Academic	17 (44.7%)	11 (34.4%)	28 (40.0%)	
Community	21 (55.3%)	21 (65.6%)	42 (60.0%)	
Stage at Diagnosis				0.57
Stage I	17 (44.7%)	10 (31.2%)	27 (38.6%)	
Stage II	2 (5.3%)	1 (3.1%)	3 (4.3%)	
Stage III	8 (21.1%)	10 (31.2%)	18 (25.7%)	
Stage IV	10 (26.3%)	11 (34.4%)	21 (30.0%)	
Unknown/not documented	1 (2.6%)	0 (0.0%)	1 (1.4%)	
Histology				< 0.001
Carcinosarcoma	2 (5.3%)	4 (12.5%)	6 (8.6%)	
Endometrial cancer, NOS	3 (7.9%)	1 (3.1%)	4 (5.7%)	
Endometrioid carcinoma	30 (78.9%)	12 (37.5%)	42 (60.0%)	
Serous carcinoma	3 (7.9%)	15 (46.9%)	18 (25.7%)	
Race				0.003
Black or African American	≤6 (≤16%)	8 (25.0%)	8 (11.4%)	
Other Race	≤6 (≤16%)	≤6 (≤19%)	9 (12.9%)	
Unknown/not documented	≤6 (≤16%)	≤6 (≤19%)	≤6 (9%)	
White	34 (89.5%)	18 (56.2%)	52 (74.3%)	
ECOG Score				0.073
0	10 (26.3%)	10 (31.2%)	20 (28.6%)	
1	10 (26.3%)	16 (50.0%)	26 (37.1%)	
2+	7 (18.4%)	2 (6.2%)	9 (12.9%)	
Unknown	11 (28.9%)	4 (12.5%)	15 (21.4%)	
dMMR by IHC				< 0.001
Loss	37 (97.4%)	5 (15.6%)	42 (60.0%)	
Normal	1 (2.6%)	27 (84.4%)	28 (40.0%)	
Opioid Use Pre-Therapy				0.762
No	20 (52.6%)	18 (56.2%)	38 (54.3%)	
Yes	18 (47.4%)	14 (43.8%)	32 (45.7%)	
ICI Line of tx				0.708
1 st	12 (31.6%)	8 (25.0%)	20 (28.6%)	
2 nd	12 (31.6%)	13 (40.6%)	25 (35.7%)	
3 rd +	14 (36.8%)	11 (34.4%)	25 (35.7%)	
TMB				< 0.001
Median (Q1, Q3)	24.1 (16.6, 32.6)	2.1 (1.3, 4.1)	12.5 (2.5, 25.7)	
PDL1				0.424
TPS 0	6 (15.8%)	4 (12.5%)	10 (14.3%)	
TPS 1-19	1 (2.6%)	3 (9.4%)	4 (5.7%)	
TPS 20+	0 (0.0%)	1 (3.1%)	1 (1.4%)	
unknown	31 (81.6%)	24 (75.0%)	55 (78.6%)	
POLE Mutation				0.473
Negative	38 (100.0%)	32 (100.0%)	70 (100.0%)	
TP53 Mutation				< 0.001
Negative	31 (81.6%)	9 (28.1%)	40 (57.1%)	
Positive	7 (18.4%)	23 (71.9%)	30 (42.9%)	
CTNNB1 mutation				0.095
Negative	24 (63.2%)	26 (81.2%)	50 (71.4%)	
Positive	14 (36.8%)	6 (18.8%)	20 (28.6%)	
BMI				0.712
Median (Q1, Q3)	28.9 (21.8, 38.5)	27.2 (22.9, 36.0)	27.3 (22.2, 37.6)	
Missing Observations	7	3	10	